Roquefort Therapeutics plc

LSE ROQ.L

Roquefort Therapeutics plc Shareholders' Equity for the year ending December 31, 2023

Roquefort Therapeutics plc Shareholders' Equity is NA for the year ending December 31, 2023. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
LSE: ROQ.L

Roquefort Therapeutics plc

CEO Mr. Trevor Ajanthan Reginald
IPO Date March 22, 2021
Location United Kingdom
Headquarters Eccleston Yards
Employees 10
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

StockViz Staff

January 15, 2025

Any question? Send us an email